<DOC>
	<DOCNO>NCT01555242</DOCNO>
	<brief_summary>This phase I , open-label , multiple dose , dose escalation study ass safety , tolerability pharmacokinetics Aneustat™ ( OMN54 ) , novel therapy , administer orally patient advance cancer lymphoma .</brief_summary>
	<brief_title>A Study Aneustat ( OMN54 ) Patients With Advanced Cancer Lymphomas</brief_title>
	<detailed_description>Patients complete 28-day cycle , may eligible continue receive Aneustat™ ( OMN54 ) 4-week increment 6 cycle ( inclusive cycle 1 ) treatment judge possible benefit ; patient experience unacceptable toxicity ; study withdrawal criterion meet .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Histological cytological evidence malignancy Male female , 18 year old Presence advance tumour , i.e. , measurable nonmeasurable disease ( RECIST criterion , version 1.1 ) recur progress follow standard therapy Able swallow oral capsule form drug Failed least one previous therapeutic regimen either longer candidate standard therapy , standard therapy available , choose pursue standard therapy . Haematology within 7 day Day 1 ( initial dose ) : Hemoglobin ( Hb ) &gt; 9.0 g/dL Platelets ≥ 100,000 cells/mm3 ( , ≥100 x 10/L ) Absolute neutrophil count ( ANC ) &gt; 1.5 cell x109/L ( , &gt; 1500 cells/mm3 ) Chemistry within 7 day Day 1 ( initial dose ) : AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 x ULN liver metastasis , AST ( SGOT ) /ALT ( SGPT ) &lt; 5 x ULN liver metastasis Bilirubin &lt; 1.5 x ULN unless Gilbert 's Syndrome Serum creatinine ≤ 1.25 ULN Coagulation within 7 day Day 1 ( initial dose ) : *INR ≤ 1.5 ECOG Performance Status 0 2 estimate life expectancy &gt; 3 month . Having initiative mean compliant protocol ( judge Principal Investigator ) within feasible geographical proximity study center make require study visit . Written inform consent obtain prior study screen procedure Females childbearing potential ( female consider childbearing potential unless postmenopausal , i.e. , menses least 12 consecutive month , without uterus ) must negative urine pregnancy test ( UPT ) within 7 day Day 1 ( initial dose ) Females childbearing potential must agree use effective method contraception ( i.e. , sexual abstinence , condom , intrauterine device , diaphragm ) Screening period throughout study participation . Patient uncontrolled symptomatic brain metastasis ( If patient brain metastasis steroid , steroid dose must stable least 30 day prior Day 1 dose ) . Use investigational medication device within 30 day initiate study therapy ( Day 1 ) . Major surgery within 30 day prior first dose ( Day 1 ) . Radiotherapy , chemotherapy , immunotherapy within 28 day prior Day 1 ( include palliative radiotherapy focal site ) . Pregnancy lactation . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure ( NY Heart Association Class III IV , see Appendix 3 ) , unstable angina pectoris , unstable cardiac arrhythmia , uncontrolled hypertension psychiatric illness/social situation would limit compliance study requirement . Screening ( within approximately 28 day registration ) 12lead electrocardiogram ( ECG ) abnormal clinically significant Refractory nausea vomiting , chronic gastrointestinal disease ( e.g. , inflammatory bowel disease ) , significant bowel resection would preclude adequate absorption . Use warfarin , i.e. , Coumadin® , Jantoven® within 7 day prior Day 1 ( initial dosing ) Intolerance aversion porcine ingredient use OMN54 oral capsule investigational medicine , OMN54 ( Aneustat™ ) . Known hypersensitivity three botanical constituent Aneustat™ ( OMN54 ) , similar plant ; plant belong Labiatae Lamiaceae family , soy , Aneustat™ ( OMN54 ) excipients Use Sophora subprostrata root ( SSR ) herba serissae within 14 day prior Day 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Advanced Cancer</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Refractory</keyword>
</DOC>